Steris (2TG) AI Stock Analysis

Company Guidance

For fiscal 2027, STERIS maintained total company as-reported revenue growth guidance of 7% to 8% and constant currency organic growth of 6% to 7%, while increasing adjusted earnings per diluted share guidance to $11.35 to $11.55 from $11.10 to $11.30, including approximately $0.18 per share benefit from tariff refunds year-to-date; Healthcare constant currency organic revenue growth is expected at 6% to 7%, AST growth at 6% to 7% compared with 7% to 8% previously, and Life Sciences constant currency organic growth at 9% to 10% compared with 6% to 7% previously. Management said AST should be somewhere in the 6% to 8% growth for that side of the business, expects procedural growth at the lower end of the range, which is somewhere around 3% instead of the high end of that range, which can be 5%, and does not expect any material additional tariff refunds during the remainder of fiscal 2027; all other elements of the most recently provided outlook remained unchanged, the outlook does not include Xodus Medical, and the go-forward model for Xodus reflects maintaining revenue growth in the mid-teens and EBIT margins in the low to mid-50s.